Stocks to Watch Today, Thursday, November 5, 2026: RITES, Nykaa, BSE, Aurobindo Pharma, Lenskart 

Mumbai, Nov 5: Here are five stocks in focus on Thursday, from 11 per cent profit decline for RITES to more than threefold jump for Nykaa to 44.9 per cent rise in profit for BSE to 32.5 per cent increase in profit for Aurobindo Pharma to 122.1 per cent surge in profit for Lenskart Solutions. Here are some key points to note from today’s session.

RITES Limited (RITES) 

RITES reported operating revenue of Rs 557 crore and EBITDA of Rs 123 crore for the September quarter of FY27. Its EBITDA margin stood at 22.1 per cent, while profit after tax (PAT) came in at Rs 97 crore, translating into a margin of 16.7 per cent on total revenue of Rs 583 crore. 

Profit fell about 11 per cent from Rs 109.10 crore a year earlier, and EBITDA was down 8 per cent from Rs 134 crore, even as operating revenue rose 1.5 per cent from Rs 549 crore. Standalone profit declines were attributed to lower exports and a change in the revenue mix. The board declared a second interim dividend of Rs 1.90 per share, with November 11 as the record date. The stock closed at Rs 197.05 on the BSE on Wednesday, up 2.02 per cent. 

Nykaa (NYKAA) 

Nykaa, operated by FSN E-Commerce Ventures, reported a more than threefold jump in net profit to Rs 101.2 crore in Q2 FY27, compared with Rs 33 crore in the corresponding quarter of the previous financial year. 

Profit rose 207 per cent and was up 27 per cent from Rs 79.76 crore in the June quarter. Revenue from operations grew 28 per cent to Rs 3,006 crore, and EBITDA rose about 65 per cent to Rs 263 crore, lifting the EBITDA margin to 8.75 per cent from 6.75 per cent. Gross merchandise value grew 30 per cent to Rs 6,151 crore, and the fashion business turned EBITDA-positive for the third straight quarter. 

BSE Limited (BSE) 

BSE Limited posted a 44.9 per cent year-on-year (YoY) growth in net profit to Rs 809.15 crore for the September quarter, against Rs 558.43 crore in the year-ago period. Revenue from operations rose 34.1 per cent to Rs 1,432.66 crore from Rs 1,068.39 crore, supported by higher transaction charges. 

EBITDA rose 42.4 per cent to Rs 984 crore, and the EBITDA margin expanded to 68.7 per cent from 64.66 per cent. Profit was about 56 per cent of revenue. Sequentially, profit fell 7.4 per cent from Rs 874.02 crore and revenue fell 8.5 per cent from Rs 1,566.02 crore, as earnings moderated from the record levels of the June quarter. The board also accepted an offer from the Mumbai Metropolitan Region Development Authority for a plot at the Bandra Kurla Complex. 

Aurobindo Pharma (AUROPHARMA) 

Aurobindo Pharma posted a 32.5 per cent YoY increase in net profit to Rs 1,124 crore for the quarter ended September 2026, compared with Rs 848 crore in the corresponding period last year. The company’s board also approved an interim dividend of Rs 7 per equity share with a face value of Re 1 each. 

Revenue from operations rose 23.9 per cent to a record Rs 10,263 crore from Rs 8,286 crore, and EBITDA grew 28.5 per cent to Rs 2,156 crore, with the margin up 75 basis points to 21 per cent. US formulations revenue rose 25 per cent to Rs 4,555 crore, Europe formulations 27 per cent to Rs 3,161 crore and active pharmaceutical ingredients 21 per cent to Rs 1,162 crore. 

Lenskart Solutions (LENSKART) 

Lenskart Solutions reported a 122.1 per cent YoY surge in consolidated profit to Rs 227.1 crore for Q2, against Rs 102.2 crore in the year-ago quarter. Revenue grew 35.7 per cent to Rs 2,845 crore from Rs 2,096.1 crore. 

Profit grew about 3.4 times as fast as revenue. Total consolidated profit after tax, including minority interests, was Rs 232.45 crore, up 124.7 per cent, and EBITDA before Ind AS 116 rose 65 per cent to Rs 392 crore, with the margin at 13.8 per cent against 11.1 per cent. Revenue rose 4.8 per cent from Rs 2,714.18 crore in the June quarter and was ahead of Motilal Oswal’s estimate of Rs 2,784.1 crore. Trailing 12-month revenue has crossed Rs 10,000 crore. 

Source

• Company exchange filings